These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26729038)

  • 1. Obesity in 2015: Advances in managing obesity.
    Dixon JB
    Nat Rev Endocrinol; 2016 Feb; 12(2):65-6. PubMed ID: 26729038
    [No Abstract]   [Full Text] [Related]  

  • 2. Obesity Week 2016 Annual Meeting.
    Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 4. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
    Cusi K
    Curr Opin Lipidol; 2016 Dec; 27(6):633-635. PubMed ID: 27805974
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
    Thompson J; Schacht S; Rothenberg F
    Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
    Schatz H
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):459-460. PubMed ID: 27701709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research digest.
    Sattar N; Preiss D
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):651. PubMed ID: 27401823
    [No Abstract]   [Full Text] [Related]  

  • 10. [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
    García SD; Sanz SD; Sanz AD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():14-9. PubMed ID: 24444519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    Rossello X; Yellon DM
    Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Lingvay I; Leiter LA
    Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
    [No Abstract]   [Full Text] [Related]  

  • 13. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
    Zimmermann J
    Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Scheen AJ
    Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Kaul S
    Circulation; 2016 Jul; 134(2):94-6. PubMed ID: 27400894
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycemic control and the heart: it matters how you get there.
    Bloomgarden Z
    J Diabetes; 2016 Jul; 8(4):453-4. PubMed ID: 26990043
    [No Abstract]   [Full Text] [Related]  

  • 17. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
    Papanas N; Tsioufis C; Maltezos ES
    Curr Vasc Pharmacol; 2016; 14(4):316-8. PubMed ID: 26924324
    [No Abstract]   [Full Text] [Related]  

  • 19. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 20. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
    Gerstein H; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.